Improving outcomes for high-risk ALL: translating new discoveries into clinical care (Q37849259)

24 August 2017

1 reference

title

Improving outcomes for high-risk ALL: translating new discoveries into clinical care (English)

1 reference

24 August 2017

4

1 reference

24 August 2017

1

Stephen P Hunger

1 reference

24 August 2017

Elizabeth A Raetz

2

1 reference

24 August 2017

Mignon L Loh

series ordinal

3

1 reference

24 August 2017

publication date

15 February 2011

1 reference

24 August 2017

published in

Pediatric Blood & Cancer

1 reference

24 August 2017

volume

56

1 reference

24 August 2017

issue

6

1 reference

24 August 2017

page(s)

984-993

1 reference

Long-term results of the pediatric oncology group studies for childhood acute lymphoblastic leukemia 1984-2001: a report from the children's oncology group

24 August 2017

cites work

1 reference

Long-term results of the children's cancer group studies for childhood acute lymphoblastic leukemia 1983-2002: a Children's Oncology Group Report

21 January 2018

1 reference

Long-term results of five consecutive trials in childhood acute lymphoblastic leukemia performed by the ALL-BFM study group from 1981 to 2000.

21 January 2018

1 reference

Treating childhood acute lymphoblastic leukemia without cranial irradiation

21 January 2018

1 reference

Acute lymphoblastic leukaemia

21 January 2018

1 reference

Risk- and response-based classification of childhood B-precursor acute lymphoblastic leukemia: a combined analysis of prognostic markers from the Pediatric Oncology Group (POG) and Children's Cancer Group (CCG).

21 January 2018

1 reference

Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia and its relationship to other prognostic factors: a Children's Oncology Group study

21 January 2018

1 reference

Factors influencing survival after relapse from acute lymphoblastic leukemia: a Children's Oncology Group study

21 January 2018

1 reference

Long-term outcome in children with relapsed ALL by risk-stratified salvage therapy: results of trial acute lymphoblastic leukemia-relapse study of the Berlin-Frankfurt-Münster Group 87.

21 January 2018

1 reference

Bone marrow recurrence after initial intensive treatment for childhood acute lymphoblastic leukemia.

21 January 2018

1 reference

Pathways through relapses and deaths of children with acute lymphoblastic leukemia: role of allogeneic stem-cell transplantation in Nordic data

21 January 2018

1 reference

Outcome after relapse among children with standard-risk acute lymphoblastic leukemia: Children's Oncology Group study CCG-1952.

21 January 2018

1 reference

Biologic pathways associated with relapse in childhood acute lymphoblastic leukemia: a Children's Oncology Group study

21 January 2018

1 reference

Genomic analysis of the clonal origins of relapsed acute lymphoblastic leukemia.

21 January 2018

1 reference

Genome-wide copy number profiling reveals molecular evolution from diagnosis to relapse in childhood acute lymphoblastic leukemia

21 January 2018

1 reference

Molecular allelokaryotyping of relapsed pediatric acute lymphoblastic leukemia.

21 January 2018

1 reference

Improved early event-free survival with imatinib in Philadelphia chromosome-positive acute lymphoblastic leukemia: a children's oncology group study

21 January 2018

1 reference

Bone marrow transplantation versus prolonged intensive chemotherapy for children with acute lymphoblastic leukemia and an initial bone marrow relapse within 12 months of the completion of primary therapy: Children's Oncology Group study CCG-1941.

21 January 2018

1 reference

Comparison of idarubicin to daunomycin in a randomized multidrug treatment of childhood acute lymphoblastic leukemia at first bone marrow relapse: a report from the Children's Cancer Group

21 January 2018

1 reference

The UK experience in treating relapsed childhood acute lymphoblastic leukaemia: a report on the medical research council UKALLR1 study.

21 January 2018

1 reference

Reinduction platform for children with first marrow relapse of acute lymphoblastic Leukemia: A Children's Oncology Group Study[corrected]

21 January 2018

1 reference

Outcome after first relapse in childhood acute lymphoblastic leukaemia - lessons from the United Kingdom R2 trial

21 January 2018

1 reference

A single high dose of idarubicin combined with high-dose ARA-C for treatment of first relapse in childhood 'high-risk' acute lymphoblastic leukaemia: a study of the AIEOP group

21 January 2018

1 reference

Outcome of patients treated for relapsed or refractory acute lymphoblastic leukemia: a Therapeutic Advances in Childhood Leukemia Consortium study

21 January 2018

1 reference

Isolated CNS relapse of acute lymphoblastic leukemia treated with intensive systemic chemotherapy and delayed CNS radiation: a pediatric oncology group study

21 January 2018

1 reference

Clinical characteristics, biologic features and outcome for young adult patients with acute lymphoblastic leukaemia

21 January 2018

1 reference

Molecular detection of minimal residual disease is a strong predictive factor of relapse in childhood B-lineage acute lymphoblastic leukemia with medium risk features. A case control study of the International BFM study group.

21 January 2018

1 reference

Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia. European Organization for Research and Treatment of Cancer--Childhood Leukemia Cooperative Group

21 January 2018

1 reference

Minimal residual disease (MRD) status prior to allogeneic stem cell transplantation is a powerful predictor for post-transplant outcome in children with ALL.

21 January 2018

1 reference

Prognostic value of minimal residual disease quantification before allogeneic stem-cell transplantation in relapsed childhood acute lymphoblastic leukemia: the ALL-REZ BFM Study Group.

21 January 2018

1 reference

Letter: A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining

21 January 2018

1 reference

Philadelphia chromosomal breakpoints are clustered within a limited region, bcr, on chromosome 22

21 January 2018

1 reference

Activation of the c-abl oncogene by viral transduction or chromosomal translocation generates altered c-abl proteins with similar in vitro kinase properties

21 January 2018

1 reference

Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome

21 January 2018

1 reference

Acute leukaemia in bcr/abl transgenic mice

21 January 2018

1 reference

Tyrosine kinase activity and transformation potency of bcr-abl oncogene products.

21 January 2018

1 reference

Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells

21 January 2018

1 reference

Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome

21 January 2018

1 reference

Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia

21 January 2018

1 reference

Acute leukemia in adolescents and young adults

21 January 2018

1 reference

Clinical outcome of children with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia treated between 1995 and 2005.

21 January 2018

1 reference

High complete remission rate and promising outcome by combination of imatinib and chemotherapy for newly diagnosed BCR-ABL-positive acute lymphoblastic leukemia: a phase II study by the Japan Adult Leukemia Study Group

21 January 2018

1 reference

Imatinib combined with induction or consolidation chemotherapy in patients with de novo Philadelphia chromosome-positive acute lymphoblastic leukemia: results of the GRAAPH-2003 study.

21 January 2018

1 reference

Discovery of N-(2-chloro-6-methyl- phenyl)-2-(6-(4-(2-hydroxyethyl)- piperazin-1-yl)-2-methylpyrimidin-4- ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays.

21 January 2018

1 reference

Foxp1 is an essential transcriptional regulator of B cell development

21 January 2018

1 reference

Genome-wide profiling of genetic alterations in acute lymphoblastic leukemia: recent insights and future directions.

21 January 2018

1 reference

Genome-wide analysis of genetic alterations in acute lymphoblastic leukaemia

21 January 2018

1 reference

High-resolution genomic profiling of childhood ALL reveals novel recurrent genetic lesions affecting pathways involved in lymphocyte differentiation and cell cycle progression.

21 January 2018

1 reference

Molecular allelokaryotyping of pediatric acute lymphoblastic leukemias by high-resolution single nucleotide polymorphism oligonucleotide genomic microarray

21 January 2018

1 reference

Acquisition of genome-wide copy number alterations in monozygotic twins with acute lymphoblastic leukemia

21 January 2018

1 reference

Deletion of IKZF1 and prognosis in acute lymphoblastic leukemia

21 January 2018

1 reference

IKZF1 deletions predict relapse in uniformly treated pediatric precursor B-ALL.

21 January 2018

1 reference

IKZF1 (Ikaros) deletions in BCR-ABL1-positive acute lymphoblastic leukemia are associated with short disease-free survival and high rate of cumulative incidence of relapse: a GIMEMA AL WP report

21 January 2018

1 reference

Stage specific over-expression of the dominant negative Ikaros 6 reveals distinct role of Ikaros throughout human B-cell differentiation.

21 January 2018

1 reference

A subtype of childhood acute lymphoblastic leukaemia with poor treatment outcome: a genome-wide classification study

21 January 2018

1 reference

JAK mutations in high-risk childhood acute lymphoblastic leukemia

21 January 2018

1 reference

Deregulated expression of cytokine receptor gene, CRLF2, is involved in lymphoid transformation in B-cell precursor acute lymphoblastic leukemia.

21 January 2018

1 reference

Rearrangement of CRLF2 in B-progenitor- and Down syndrome-associated acute lymphoblastic leukemia

21 January 2018

1 reference

Rearrangement of CRLF2 is associated with mutation of JAK kinases, alteration of IKZF1, Hispanic/Latino ethnicity, and a poor outcome in pediatric B-progenitor acute lymphoblastic leukemia

21 January 2018

1 reference

Thymic stromal lymphopoietin: master switch for allergic inflammation

21 January 2018

1 reference

Functional screening identifies CRLF2 in precursor B-cell acute lymphoblastic leukemia

21 January 2018

1 reference

Down syndrome acute lymphoblastic leukemia, a highly heterogeneous disease in which aberrant expression of CRLF2 is associated with mutated JAK2: a report from the International BFM Study Group

21 January 2018

1 reference

Gene expression classifiers for relapse-free survival and minimal residual disease improve risk classification and outcome prediction in pediatric B-precursor acute lymphoblastic leukemia

21 January 2018

1 reference

Role of JAK2 in the pathogenesis and therapy of myeloproliferative disorders

21 January 2018

1 reference

The JAK kinase inhibitor CP-690,550 suppresses the growth of human polycythemia vera cells carrying the JAK2V617F mutation

21 January 2018

1 reference

Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms

21 January 2018

1 reference

Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis

21 January 2018

1 reference

Single-cell profiling identifies aberrant STAT5 activation in myeloid malignancies with specific clinical and biologic correlates

21 January 2018

1 reference

Therapeutic potential of JAK2 inhibitors

21 January 2018

1 reference

BCR–ABL1 lymphoblastic leukaemia is characterized by the deletion of Ikaros

21 January 2018

1 reference

A cellular oncogene is translocated to the Philadelphia chromosome in chronic myelocytic leukaemia

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1002/PBC.22996

1 reference

24 August 2017

1 reference